2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Melanoma
18
Neoplasm Metastasis
16
Carcinoma, Hepatocellular
15
Neoplasms
13
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Colorectal Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Small Cell Lung Carcinoma
5
Recurrence
5
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Liver Neoplasms
4
Glioblastoma
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
4
napabucasin
3
Paclitaxel
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
lenvatinib
2
entinostat
2
anlotinib
2
Taxes
2
Sunitinib
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Carboplatin
2
vorasidenib
1
sipuleucel-T
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
linifanib
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled